New hope for tough stomach cancers: testing a Triple-Threat treatment
NCT ID NCT07490990
Summary
This study is testing a three-part treatment for people with advanced HER2-positive stomach cancer that has worsened after two prior standard treatments. It combines a targeted drug (disitamab vedotin), an immunotherapy drug, and a specialized form of radiation therapy. The goal is to see if this combination can better control the cancer's growth and extend patients' lives.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE ADVANCED GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.